GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-10-21
- Last Posted Date
- 2023-01-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 300
- Registration Number
- NCT05087056
- Locations
- 🇩🇪
GSK Investigational Site, Schweigen-Rechtenbach, Germany
A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age
Phase 2
Completed
- Conditions
- Interventions
- Biological: Investigational varicella vaccine high potencyBiological: Marketed varicella vaccine Lot 1Biological: Investigational varicella vaccine low potencyBiological: Investigational varicella vaccine medium potencyBiological: Marketed varicella vaccine Lot 2Biological: Measles, mumps, and rubella vaccineBiological: Hepatitis A vaccineBiological: 13-valent pneumococcal conjugate vaccine
- First Posted Date
- 2021-10-19
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 800
- Registration Number
- NCT05084508
- Locations
- 🇨🇳
GSK Investigational Site, Taoyuan, Taiwan
A Study on the Safety, Tolerability and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Infants
- First Posted Date
- 2021-10-18
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 724
- Registration Number
- NCT05082285
- Locations
- 🇬🇧
GSK Investigational Site, Manchester, United Kingdom
A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants
Phase 1
Recruiting
- Conditions
- Interventions
- Biological: altSonflex1-2-3 Dose CBiological: GSK's Meningococcal A, C, Y and W-135 conjugate vaccineBiological: altSonflex1-2-3 Dose ABiological: altSonflex1-2-3 Dose BDrug: altSonflex PlaceboCombination Product: GSK's Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b vaccineCombination Product: GSK's Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccineCombination Product: Sanofi Pasteur's Typhoid Vi polysaccharide vaccineBiological: Serum Institute of India's Measles and rubella vaccine
- First Posted Date
- 2021-10-11
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 550
- Registration Number
- NCT05073003
- Locations
- 🇰🇪
GSK Investigational Site, Kericho, Kenya
Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2021-10-01
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 177
- Registration Number
- NCT05064358
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
A Study of 3 Lots of an Investigational Vaccine Against Respiratory Syncytial Virus (RSV) in Adults Aged 60 Years and Above
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-09-28
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 770
- Registration Number
- NCT05059301
- Locations
- 🇸🇪
GSK Investigational Site, Uppsala, Sweden
A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 2013
- Registration Number
- NCT05047770
- Locations
- 🇺🇸
GSK Investigational Site, Tacoma, Washington, United States
A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.
- First Posted Date
- 2021-09-16
- Last Posted Date
- 2023-10-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1586
- Registration Number
- NCT05045144
- Locations
- 🇪🇸
GSK Investigational Site, Valencia, Spain
A First Time in Human (FTIH) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of GSK3884464 in Healthy Participants
- First Posted Date
- 2021-09-14
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 27
- Registration Number
- NCT05044325
- Locations
- 🇬🇧
GSK Investigational Site, Cambridge, United Kingdom
A Study on the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 to 49 Years and Infants Born to the Vaccinated Mothers
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2021-07-28
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 384
- Registration Number
- NCT04980391
- Locations
- 🇪🇸
GSK Investigational Site, Torrejón Ardoz, Spain
© Copyright 2024. All Rights Reserved by MedPath